Chimeric: Media Thread, page-174

Further upside (The Money Shot)

RaaS believes that further upside could be obtained from:

➢ The advancement of CHM 1101 to Phase II with GBM;

➢ The commencement of a Phase I frontline GBM study;

➢ The application of CHM 1101 to other indications;

➢ The advancement of CDH17 CAR T from pre-clinical stage to Phase I and beyond; and

➢ From the acquisition of additional portfolio opportunities.

Chimeric has identified melanoma, colorectal and prostate cancers as potential further targets but these are in the pre-clinical stage.

Additionally, CDH17 CAR T (CHM 2101) has set initial indications of colorectal, pancreatic, gastric and neuroendocrine cancers for its pre-clinical studies.

Chimeric has also indicated that it is seeking to expand the portfolio with additional acquisitions, which depending on their level of advancement, could add to our valuation range.